Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS)
Beijing, CN
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. operates as a contract research organization (CRO) in China, primarily focused on the development of chemical and peptide-based pharmaceutical products. Its portfolio includes generic small-molecule chemical drugs and peptide therapies designed to treat a range of conditions such as impetigo, acne, renal anemia, hyperparathyroidism in chronic kidney disease patients on dialysis, and various pain-related ailments. Beyond drug development, the company offers a comprehensive array of research and evaluation services. These encompass testing for packaging material compatibility, detailed impurity profiling, extractables and leachables studies, and thorough safety assessments. Sun-Novo also provides support for consistency evaluations, facilitates clinical research, and delivers expert consulting and agency services for regulatory submissions. Furthermore, it conducts a full spectrum of GLP-compliant bioanalysis and pharmacokinetics-pharmacodynamics (PK/PD) studies, including pharmacokinetic, immunogenic, pharmacodynamic, and biomarker analyses. The company was founded in 2009 and is headquartered in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.30% | -4.90% | -6.38% | -17.30% | -18.37% | -13.11% | -3.23% | -12.54% | -37.05% | -37.05% | -37.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+12.9% ★ Q1'26: -14.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+17.7% ★ Q1'26: -33.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-10.2% Q1'26: -40.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+18.5% ★ Q1'26: +10.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+17.7% ★ Q1'26: +5.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-2.4% ★ Q1'26: +4.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.08× Q1'26: 7.24× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
493.65M
est: 498.50M (-1.0%)
|
676.61M
est: 680.50M (-0.6%)
|
932.12M
est: 954.00M (-2.3%)
|
1.08B
est: 1.20B (-10.2%)
|
1.22B
est: 1.18B (+3.3%)
|
1.37B
1.37B – 1.37B
+16.3% YoY
|
1.51B
1.51B – 1.51B
+10.2% YoY
|
1.61B
1.61B – 1.61B
+6.2% YoY
|
| EBITDA |
137.21M
est: 120.11M (+14.2%)
|
196.07M
est: 163.96M (+19.6%)
|
227.64M
est: 229.86M (-1.0%)
|
217.53M
est: 298.17M (-27.0%)
|
277.26M
est: 292.71M (-5.3%)
|
340.37M
340.37M – 340.37M
+16.3% YoY
|
375.13M
375.13M – 375.13M
+10.2% YoY
|
398.47M
398.47M – 398.47M
+6.2% YoY
|
| EBIT |
125.71M
est: 107.81M (+16.6%)
|
179.02M
est: 147.18M (+21.6%)
|
205.63M
est: 206.33M (-0.3%)
|
192.15M
est: 264.93M (-27.5%)
|
225.21M
est: 260.07M (-13.4%)
|
302.43M
302.43M – 302.43M
+16.3% YoY
|
333.31M
333.31M – 333.31M
+10.2% YoY
|
354.05M
354.05M – 354.05M
+6.2% YoY
|
| Net Income |
105.66M
est: 110.68M (-4.5%)
|
156.47M
est: 155.39M (+0.7%)
|
184.76M
est: 194.25M (-4.9%)
|
177.41M
est: 232.23M (-23.6%)
|
203.87M
est: 197.18M (+3.4%)
|
232.23M
232.23M – 232.23M
+17.8% YoY
|
282.62M
282.62M – 282.62M
+21.7% YoY
|
303.44M
303.44M – 303.44M
+7.4% YoY
|
| SGA |
85.20M
est: 79.01M (+7.8%)
|
110.81M
est: 107.85M (+2.7%)
|
153.24M
est: 151.20M (+1.3%)
|
150.44M
est: 172.36M (-12.7%)
|
94.13M
est: 169.20M (-44.4%)
|
196.76M
196.76M – 196.76M
+16.3% YoY
|
216.85M
216.85M – 216.85M
+10.2% YoY
|
230.34M
230.34M – 230.34M
+6.2% YoY
|
| EPS |
1.08
est: 0.99 (+9.6%)
|
1.40
est: 1.38 (+1.2%)
|
1.65
est: 1.73 (-4.6%)
|
1.58
est: 2.12 (-25.5%)
|
1.86
est: 1.80 (+3.3%)
|
2.12
2.12 – 2.12
+17.8% YoY
|
2.58
2.58 – 2.58
+21.7% YoY
|
2.77
2.77 – 2.77
+7.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 2/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 2/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 2/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dao Sheng Xie | Core Technical Staff | — | male |
| Guangtao Hao | Deputy GM & Core Technician | — | male |
| Huan Luo | Deputy GM & Director | — | male |
| Li Ping Wei | Secretary & Director | — | female |
| Ming Juan Wang | Core Technical Staff | — | female |
| Yan Shao | Deputy General Manager | — | female |
| Yuanbo Li | Deputy General Manager | — | male |
| Yujing Liu | GM & Director | — | male |
| Zhi Jiao Zhang | Accounting Supervisor & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688621.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
